PT  - JOURNAL ARTICLE
AU  - Ioannou, George N.
AU  - Bohnert, Amy SB
AU  - O’Hare, Ann M.
AU  - Boyko, Edward J.
AU  - Maciejewski, Matthew L.
AU  - Smith, Valerie A.
AU  - Bowling, C. Barrett
AU  - Viglianti, Elizabeth
AU  - Iwashyna, Theodore J.
AU  - Hynes, Denise M.
AU  - Berry, Kristin
AU  - ,
TI  - Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization and death: a target trial emulation in the omicron (B.1.1.529) variant era
AID  - 10.1101/2022.06.15.22276466
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.15.22276466
4099  - http://medrxiv.org/content/early/2022/06/16/2022.06.15.22276466.short
4100  - http://medrxiv.org/content/early/2022/06/16/2022.06.15.22276466.full
AB  - Background The effectiveness of a 3rd mRNA COVID-19 vaccine (“booster”) dose against the omicron (B.1.1.529) variant is uncertain especially in older, high-risk populations.Objective To determine mRNA booster vaccine effectiveness (VE) against SARS-CoV-2 infection, hospitalization and death in the omicron era by type of booster, type of primary vaccine, time since primary vaccine, age and comorbidity burden.Design Target trial emulation study comparing booster vaccination versus no booster.Setting U.S. Department of Veterans Affairs (VA) healthcare systemParticipants and Intervention Among persons who had received two mRNA COVID-19 vaccine doses at least 5 months earlier, we designed this retrospective matched cohort study to emulate a target trial of booster mRNA vaccination (BNT162b2 or mRNA-1273) versus no booster, conducted from 12/01/2021 to 03/31/2022.Measurements Booster VE.Results Each group included 490,838 well-matched persons, predominantly male (88%), mean age 63.0±14.0 years, followed for up to 121 days (mean 79.8 days). Booster VE >10 days after booster was 42.3% (95% CI 40.6-43.9) against SARS-CoV-2 infection, 53.3% (48.1-58.0) against SARS-CoV-2-related hospitalization and 79.1% (71.2-84.9) against SARS-CoV-2-related death. Booster VE was similar for different booster types (BNT162b2 or mRNA-1273), age groups or primary vaccination regimens, but was significantly higher with longer time since primary vaccination and with higher comorbidity burden.Limitations Predominantly male population.Conclusions Booster mRNA vaccination was highly effective in preventing death and moderately effective in preventing infection and hospitalization for up to 4 months after administration in the omicron era. Increased uptake of booster vaccination, which is currently suboptimal, should be pursued to limit the morbidity and mortality of SARS-CoV-2 infection, especially in persons with high comorbidity burden.Primary Funding Source: Department of Veterans AffairsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the Department of Veterans Affairs, Office of Research and Development HSR&D grants C19 21-278 to GNI, ASB, EJB and MLM; C19 21-279 to AMO, CBB, TI, DMH and EV; RCS 10-391 to MLM; RCS 21-136 to DMH; and COVID19-8900-11 to GNI. Support for VA/CMS data is provided by the Department of Veterans Affairs, VA Health Services Research and Development Service, VA Information Resource Center (Project Numbers SDR 02-237 and 98-004) The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Veterans Affairs Puget Sound Healthcare System gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present study are available only to investigators who have appropriate regulatory approval according to the regulations of the Veterans Affairs Office of Research and DevelopmentData produced in the present study are available only to investigators who have appropriate regulatory approval according to the regulations of the Veterans Affairs Office of Research and Development